Business

MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference

MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics

articleMimedx Group, IncDecember 22, 20215/company/mimedx-group-inc/news/mimedx-to-present-at-the-40th-annual-jp-morgan-healthcare-conference-2021-12-22
MIMEDX to Present at the 40th Annual J.P. Morgan Healthcare Conference

About this update from Mimedx Group, Inc

[{"type":"text","content":"MARIETTA, Ga., Dec. 22, 2021 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that Timothy R. Wright, Chief Executive Officer, and Peter M. Carlson, Chief Financial Officer, will present during the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12 at 5:15 PM EST. Institutional investors interested in a virtual meeting with management during the conference may reach out to their J.P. Morgan representative. Investors and other interested parties may access the live webcast on the Events page of the Investors section of the Company’s website or by clicking here. A replay of the webcast will be available for 30 days on the Company’s website at www.mimedx.com following the conclusion of the presentation. About MIMEDXMIMEDX is a transformational placental biologics company, developing and distributing placental tissue allografts with patent-protected, proprietary processes for multiple sectors of healthcare. As a pioneer in placental tissue engineering, we have both a commercial business, focused on addressing the needs of patients with acute and chronic non-healing wounds, and a promising late-stage pipeline targeted at decreasing pain and improving function for patients with degenerative musculoskeletal conditions. We derive our products from human placental tissues and process these tissues using our proprietary methods, including the PURION® process. We employ Current Good Tissue Practices, Current Good Manufacturing Practices, and terminal sterilization to produce our allografts. MIMEDX has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com. Contact:Jack HowarthInvestor [email protected] Contact:Hilary DixonCorporate & Strategic [email protected] \nSource: MiMedx Group, Inc","length":4436,"tagName":"div"}]

More updates from Mimedx Group, Inc